Drug intelligence / Profile preview

211At-rituximab

Development stage: Preclinical
Lead developer: Oslo University Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**211At-rituximab** is an experimental targeted alpha-radioimmunotherapy consisting of the anti-CD20 monoclonal antibody rituximab covalently labeled with the alpha-particle-emitting radionuclide astatine-211. Binding of the rituximab component to CD20-positive B-cell lymphoma cells localizes high-linear-energy-transfer alpha radiation to malignant B cells, causing lethal DNA damage over a short tissue range. It has been evaluated in preclinical non-Hodgkin lymphoma models, including selective in-vitro cytotoxicity studies in human B-lymphoma cell lines and mouse biodistribution experiments; it is not an approved therapeutic product.

Other names: 211At-labelled rituximab211At-rituximabastatine-211-rituximabastatine211-rituximabastatine 211-rituximab

Targets

CD20 (B-lymphocyte antigen CD20)DNA

Beyond the preview

Go deeper on 211At-rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 211At-rituximab.

Explore the full profile